Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study
Status:
Withdrawn
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate in a step-wise approach the disease drug-drug
interaction (DDI) potential for vedolizumab to indirectly affect the exposure of cytochrome
P-450 (CYP) substrate drugs by modulating pro-inflammatory cytokines in participants with
ulcerative colitis (UC) or Crohn's disease (CD) who are treated with vedolizumab.